The Cancer Letter

Inside information on cancer research and drug development

In Brief

Senate confirms Stephen Hahn as FDA commissioner

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The Senate Dec. 12 voted 72-18 to confirm Stephen Hahn as FDA commissioner.

Hahn, 59, is chief medical executive at MD Anderson Cancer Center and professor in the Department of Radiation Oncology.

On Dec. 3, members of the Senate Committee on Health Education Labor and Pensions voted 18-5 to confirm Hahn (The Cancer Letter, Dec. 6). The White House announced its intention to nominate Hahn Nov. 1 (The Cancer Letter, Sept. 6, Nov. 1).

In his Senate confirmation hearing Nov. 20, Hahn acknowledged that the rise in e-cigarette use among youths “is an important, urgent crisis in this country,” but made no specific pledges as Democratic and Republican Senate members pressed him on whether he would resist pressure from the administration and lobbying groups. (The Cancer Letter, Nov. 22).

Once sworn in, Hahn will become the 24th FDA commissioner, succeeding Scott Gottlieb.

Table of Contents

YOU MAY BE INTERESTED IN

Guest Editorial

Call to action: To address Black cancer disparities, focus on research prioritization and clinical studies inclusion
Minority Cancer Awareness Week

People of African ancestry (Black/African American) have some of the worst cancer incidence and greatest mortality, compared to white and other racial and ethnic populations in the U.S. On average, Black persons are 1.5 times more likely to have cancer and >2X more likely to die from cancer compared to whites. xxx:more
By Kimlin Tam Ashing, Nadine J. Barrett, Kim F. Rhoads, Folakemi T. Odedina, Hayley S. Thompson and Camille C. R. Ragin
Table of Contents

Login

Looking for IP Login?